Get started
PROKIDNEY CORPPROKIDNEY CORPPROKIDNEY CORP

PROKIDNEY CORP

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PROK/N chart


Full chart

PROK/N upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.35 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−13.11 MXN
Net income (FY)
‪−1.28 B‬ MXN
Revenue (FY)
‪1.58 M‬ MXN
Shares float
‪93.47 M‬
Beta (1Y)
3.37

Employees


Employees (FY)
204
Change (1Y)
+41 +25.15%
Revenue / Employee (1Y)
‪7.77 K‬ MXN
Net income / Employee (1Y)
‪−6.25 M‬ MXN

About ProKidney Corp.


Sector
Health Technology
Industry
Biotechnology
CEO
Bruce Culleton
Website
prokidney.com
Headquarters
Winston-Salem
Founded
2015
FIGI
BBG014RL5BZ6
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PROK/N news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as PROK/N.

Frequently Asked Questions


The current price of PROK/N is 15.00 MXN — it has decreased by −16.67% in the past 24 hours. Watch PROKIDNEY CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange PROKIDNEY CORP stocks are traded under the ticker PROK/N.
PROK/N stock has fallen by −16.67% compared to the previous week, the month change is a −53.93% fall, over the last year PROKIDNEY CORP has showed a −42.31% decrease.
We've gathered analysts' opinions on PROKIDNEY CORP future price: according to them, PROK/N price has a max estimate of 120.42 MXN and a min estimate of 60.21 MXN. Watch PROK/N chart and read a more detailed PROKIDNEY CORP stock forecast: see what analysts think of PROKIDNEY CORP and suggest that you do with its stocks.
PROK/N reached its all-time high on Jan 26, 2023 with the price of 202.55 MXN, and its all-time low was 18.00 MXN and was reached on Apr 3, 2025. View more price dynamics on PROK/N chart.
See other stocks reaching their highest and lowest prices.
PROK/N stock is 20.00% volatile and has beta coefficient of 3.37. Track PROKIDNEY CORP stock price on the chart and check out the list of the most volatile stocks — is PROKIDNEY CORP there?
Today PROKIDNEY CORP has the market capitalization of ‪1.93 B‬, it has decreased by −27.41% over the last week.
Yes, you can track PROKIDNEY CORP financials in yearly and quarterly reports right on TradingView.
PROKIDNEY CORP is going to release the next earnings report on May 9, 2025. Keep track of upcoming events with our Earnings Calendar.
PROK/N earnings for the last quarter are −3.34 MXN per share, whereas the estimation was −3.09 MXN resulting in a −7.99% surprise. The estimated earnings for the next quarter are −3.20 MXN per share. See more details about PROKIDNEY CORP earnings.
PROKIDNEY CORP revenue for the last quarter amounts to ‪1.58 M‬ MXN, matching the estimated figure, and no changes in revenue are expected for the next quarter.
PROK/N net income for the last quarter is ‪−443.63 M‬ MXN, while the quarter before that showed ‪−352.89 M‬ MXN of net income which accounts for −25.71% change. Track more PROKIDNEY CORP financial stats to get the full picture.
No, PROK/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 204 employees. See our rating of the largest employees — is PROKIDNEY CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PROKIDNEY CORP EBITDA is ‪−3.63 B‬ MXN, and current EBITDA margin is ‪−228.97 K‬%. See more stats in PROKIDNEY CORP financial statements.
Like other stocks, PROK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PROKIDNEY CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PROKIDNEY CORP technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PROKIDNEY CORP stock shows the strong sell signal. See more of PROKIDNEY CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.